HC Wainwright Reaffirms Buy Rating for Evolus (NASDAQ:EOLS)

Evolus (NASDAQ:EOLS)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They currently have a $27.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 57.53% from the stock’s current price.

A number of other equities analysts have also weighed in on EOLS. Barclays boosted their target price on Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Needham & Company LLC reissued a “buy” rating and set a $22.00 price objective on shares of Evolus in a report on Friday, September 13th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Evolus in a research report on Monday, September 16th.

Evolus Trading Up 0.7 %

NASDAQ:EOLS opened at $17.14 on Thursday. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -16.32 and a beta of 1.31. The company has a quick ratio of 2.67, a current ratio of 2.92 and a debt-to-equity ratio of 6.26. The company’s 50 day moving average price is $14.85 and its 200-day moving average price is $13.21. Evolus has a 52 week low of $7.44 and a 52 week high of $17.70.

Evolus (NASDAQ:EOLS) last issued its earnings results on Wednesday, July 31st. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The business had revenue of $66.91 million during the quarter, compared to analyst estimates of $65.06 million. On average, equities research analysts forecast that Evolus will post -0.64 earnings per share for the current fiscal year.

Insider Transactions at Evolus

In related news, CFO Sandra Beaver sold 3,276 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the sale, the chief financial officer now directly owns 148,502 shares in the company, valued at $2,224,559.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of Evolus stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $15.85, for a total transaction of $89,251.35. Following the transaction, the chief marketing officer now directly owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the sale, the chief financial officer now directly owns 148,502 shares of the company’s stock, valued at $2,224,559.96. The disclosure for this sale can be found here. Company insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Evolus

A number of hedge funds have recently modified their holdings of the company. Perceptive Advisors LLC boosted its holdings in Evolus by 166.8% in the 4th quarter. Perceptive Advisors LLC now owns 3,963,424 shares of the company’s stock worth $41,735,000 after buying an additional 2,477,623 shares during the period. Assenagon Asset Management S.A. lifted its position in shares of Evolus by 5,627.2% in the second quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock valued at $10,276,000 after acquiring an additional 930,566 shares in the last quarter. Lord Abbett & CO. LLC bought a new position in shares of Evolus in the first quarter worth about $11,628,000. BNP Paribas Financial Markets grew its position in shares of Evolus by 84.2% during the first quarter. BNP Paribas Financial Markets now owns 405,931 shares of the company’s stock worth $5,683,000 after purchasing an additional 185,532 shares in the last quarter. Finally, Armistice Capital LLC bought a new stake in Evolus during the 2nd quarter valued at approximately $3,906,000. 90.69% of the stock is currently owned by institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.